“It’s time to reorient the mindset around Pharmaceutical Benefits Scheme reimbursement. Australians with a clear medical need should not miss out on access to an innovative medicine with proven clinical benefit because the patient pool is considered too large to allow for Government funding,” said Eli Lilly general manager Tori Brown.
'A procurement mindset must not impede equitable access to medicines that offer significant benefits'
November 14, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News -
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech

